Anna Härle

Anna Härle

Auto-generated profile, based on publicly available information

Anna Härle

Ulm University Hospital 1 Institute of Molecular Oncology and Stem Cell Biology Ulm, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2025 in Advanced Science
Verified
Journal Article
Open access
DSDharini Srinivasan
Dharini Srinivasan
ERElodie Roger
Elodie Roger
LPLukas Perkhofer
Lukas Perkhofer
EZEleni Zimmer
Eleni Zimmer
TBThomas F.E. Barth
Thomas F.E. Barth
AKAlexander Kleger
Alexander Kleger
Pancreatic ductal adenocarcinoma (PDAC) is characterized by its intricate biology governed by spatiotemporal dynamics in the expression and function of specific proteins. Here, DKK3 is identified as a dynamic player with a dual role in PDAC. Using the KRAS G12D ‐driven mouse model with homozygous (DDKC) and heterozygous (DKC) DKK3 knockout, its stage and compartment‐specific functions are investigated. Knockout mice exhibited shorter lifespans with a higher incidence of high‐grade, desmoplastic, and metastatic cancers. DKK3‐deficient acini exhibited a marked increase in acinar‐to‐ductal metaplasia, with increased MAPK signaling and induction of the downstream effector Fos . During the progression of mouse and human PDAC, DKK3 expression shifted from epithelial dysplastic cells to cancer‐associated fibroblasts (CAFs). At the endpoint, DKK3‐expressing CAFs emerged as crucial contributors to tumor aggressiveness and fibrosis. Orthotopic transplantations confirm a stromal role, particularly in DDKC tumors, while mechanistic studies demonstrate that DKK3 activates IL6‐JAK‐STAT3 signaling and pro‐migratory/mesenchymal programs that are reversed by pharmacologic STAT3 inhibition in DDKC cells. Concordantly, DKK3 expression correlates with IL6‐JAK‐STAT3 gene signatures in human PDAC datasets. Together, these findings underscore the intricate and context‐sensitive role of DKK3, delaying oncogenesis during early stages while paradoxically promoting tumor progression in later stages, suggesting that therapeutic targeting strategies should be approached with caution.

15 June 2026 in Cancer Research
Verified
Journal Article
Open access
ERElodie Roger
Elodie Roger
HMHannah M. Mummey
Hannah M. Mummey
EZEleni Zimmer
Eleni Zimmer
DSDharini Srinivasan
Dharini Srinivasan
AHAnna Härle
Anna Härle
AKAlexander Kleger
Alexander Kleger
The tumor microenvironment (TME) actively contributes to pancreatic ductal adenocarcinoma (PDAC) pathogenesis through dynamic bidirectional tumor–stroma interactions. In this study, we demonstrated that ATM-deficient tumor epithelium reprograms the TME in a genotype-specific manner to enhance cancer aggressiveness. In genetically engineered mouse models, pancreatic stellate cell and cancer-associated fibroblast (CAF) coculture systems, single-nucleus multiomics, and human PDAC models, tumoral loss of ATM serine/threonine kinase drove CAFs toward αSMA+ myofibroblastic (myCAF) differentiation, independently of p53 status. The myCAFs, in turn, promoted cancer aggressiveness and chemoresistance. Mechanistically, ATM deficiency increased reactive oxygen species and contractility signaling, enhancing TGFβ1 secretion. Pharmacologic TGFβ inhibition reversed myCAF differentiation, sensitized tumors to chemotherapy, and impaired tumor progression in both murine and human ATM-null models. These findings reveal that ATM-deficient tumors shape a cancer-promoting niche via TGFβ signaling and identify dual targeting of intrinsic and extrinsic vulnerabilities as a promising precision oncology strategy. Significance: TGF-β-driven myofibroblastic stromal differentiation in ATM-deficient pancreatic cancer generates a genotype-specific tumor microenvironment, providing a targetable axis and highlighting the need to integrate epithelial genotype and stromal context in pancreatic cancer therapy.

15 July 2026
Verified
Other
Open access
ERElodie Roger
Elodie Roger
HMHannah M. Mummey
Hannah M. Mummey
EZEleni Zimmer
Eleni Zimmer
DSDharini Srinivasan
Dharini Srinivasan
AHAnna Härle
Anna Härle
AKAlexander Kleger
Alexander Kleger
ROS measurements, cytoskeletal marker expression, migration assays, and PSC differentiation analyses following genetic and pharmacologic perturbation of ROS and cytoskeletal pathways in ATM-deficient tumor models.

15 July 2026
Verified
Other
Open access
ERElodie Roger
Elodie Roger
HMHannah M. Mummey
Hannah M. Mummey
EZEleni Zimmer
Eleni Zimmer
DSDharini Srinivasan
Dharini Srinivasan
AHAnna Härle
Anna Härle
AKAlexander Kleger
Alexander Kleger
PSC-induced chemotherapy resistance and in vitro and ex vivo assays assessing apoptosis, invasion, wound closure, and drug response after perturbation of tumor–CAF signaling.

15 July 2026
Verified
Other
Open access
ERElodie Roger
Elodie Roger
HMHannah M. Mummey
Hannah M. Mummey
EZEleni Zimmer
Eleni Zimmer
DSDharini Srinivasan
Dharini Srinivasan
AHAnna Härle
Anna Härle
AKAlexander Kleger
Alexander Kleger
Clinical characteristics and mutation profiles of the patient-derived organoids used in this study.

15 July 2026
Verified
Other
Open access
ERElodie Roger
Elodie Roger
HMHannah M. Mummey
Hannah M. Mummey
EZEleni Zimmer
Eleni Zimmer
DSDharini Srinivasan
Dharini Srinivasan
AHAnna Härle
Anna Härle
AKAlexander Kleger
Alexander Kleger
Clustering, quality control metrics, and immune cell subset annotation from single-nucleus multiomic profiling of KPC and AKPC tumors.